Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31339572,m/,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,130.1,9977,DB08907,Canagliflozin
,31339572,m/,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,71.1,9978,DB08907,Canagliflozin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,462.0,9979,DB08907,Canagliflozin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,191.2,9980,DB08907,Canagliflozin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,426.1,9981,DB08907,Canagliflozin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,167.1,9982,DB08907,Canagliflozin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,468.0,9983,DB08907,Canagliflozin
,31339572,m/z,"Quantification was performed in multiple reaction monitoring mode using m/z 130.1 → 71.1 for metformin, m/z 462.0 → 191.2 for canagliflozin, m/z 426.1 → 167.1 for dapagliflozin and m/z 468.0 → 354.9 for empagliflozin.",A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31339572/),,354.9,9984,DB08907,Canagliflozin
,32763846,flow rate,"The mobile phase consisted of methanol and 5 mM ammonium trifluoroacetate in water, pH 5 (50:50, v/v) at a flow rate of 0.8 mL/min.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),[ml] / [min],0.8,44256,DB08907,Canagliflozin
,32763846,m/z,"Also, for metformin transitions were monitored at m/z 130.0 → m/z 71.1.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),,71.1,44257,DB08907,Canagliflozin
,32763846,Linearity,Linearity was in the range of 24.95-2806.55 ng/mL for canagliflozin and 24.99-3400.72 ng/mL for metformin.,Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),[ng] / [ml],24.95-2806.55,44258,DB08907,Canagliflozin
,32763846,Linearity,Linearity was in the range of 24.95-2806.55 ng/mL for canagliflozin and 24.99-3400.72 ng/mL for metformin.,Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),[ng] / [ml],24.99-3400.72,44259,DB08907,Canagliflozin
,32763846,extraction recovery,"The mean extraction recovery of canagliflozin, canagliflozin D4, metformin, and metformin D6 was 77.240, 84.663, 66.747, and 67.449, respectively across four QC levels.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),,77.240,44260,DB08907,Canagliflozin
,32763846,extraction recovery,"The mean extraction recovery of canagliflozin, canagliflozin D4, metformin, and metformin D6 was 77.240, 84.663, 66.747, and 67.449, respectively across four QC levels.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),,84.663,44261,DB08907,Canagliflozin
,32763846,extraction recovery,"The mean extraction recovery of canagliflozin, canagliflozin D4, metformin, and metformin D6 was 77.240, 84.663, 66.747, and 67.449, respectively across four QC levels.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),,66.747,44262,DB08907,Canagliflozin
,32763846,extraction recovery,"The mean extraction recovery of canagliflozin, canagliflozin D4, metformin, and metformin D6 was 77.240, 84.663, 66.747, and 67.449, respectively across four QC levels.",Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),,67.449,44263,DB08907,Canagliflozin
,32763846,run time,This rapid method with the run time of 2.80 min allows the analysis of more than 400 plasma samples per day.,Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763846/),min,2.80,44264,DB08907,Canagliflozin
,25500487,min,"The relationship between drug concentrations and RTG was described by a sigmoidal relationship with RTGmin (minimum value of RTG) of 37.5 ng/mL (95% confidence interval (CI): 34.3, 40.8) and half-maximal effective concentration (EC50) of 21 ng/mL (95% CI: 18.3, 23.8).","Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500487/),ng,37.5,48536,DB08907,Canagliflozin
,25500487,half-maximal effective concentration (EC50),"The relationship between drug concentrations and RTG was described by a sigmoidal relationship with RTGmin (minimum value of RTG) of 37.5 ng/mL (95% confidence interval (CI): 34.3, 40.8) and half-maximal effective concentration (EC50) of 21 ng/mL (95% CI: 18.3, 23.8).","Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500487/),[ng] / [ml],21,48537,DB08907,Canagliflozin
,31362250,extraction recovery,The extraction recovery ranged from 79 to 88% for all the analytes.,Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31362250/),%,79 to 88,50267,DB08907,Canagliflozin
,27136910,Cmax,"After oral administration, the mean (SD) Cmax of canagliflozin was 2504 (482) ng/mL at 1.5 hours, AUC∞ 17,375 (3555) ng.h/mL, and t1/2 11.6 (0.70) hours.",Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),[ng] / [ml],2504,51606,DB08907,Canagliflozin
,27136910,AUC∞,"After oral administration, the mean (SD) Cmax of canagliflozin was 2504 (482) ng/mL at 1.5 hours, AUC∞ 17,375 (3555) ng.h/mL, and t1/2 11.6 (0.70) hours.",Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),[h·ng] / [ml],"17,375",51607,DB08907,Canagliflozin
,27136910,t1/2,"After oral administration, the mean (SD) Cmax of canagliflozin was 2504 (482) ng/mL at 1.5 hours, AUC∞ 17,375 (3555) ng.h/mL, and t1/2 11.6 (0.70) hours.",Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),h,11.6,51608,DB08907,Canagliflozin
,27136910,Cmax,"After intravenous administration, the mean (SD) Cmax of unchanged [(14) C]-canagliflozin was 17,605 (6901) ng/mL, AUC∞ 27,100 (10,778) ng.h/mL, Vdss 83.5 (29.2) L, Vdz 119 (41.6) L, and CL 12.2 (3.79) L/h.",Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),[ng] / [ml],"17,605",51609,DB08907,Canagliflozin
,27136910,AUC∞,"After intravenous administration, the mean (SD) Cmax of unchanged [(14) C]-canagliflozin was 17,605 (6901) ng/mL, AUC∞ 27,100 (10,778) ng.h/mL, Vdss 83.5 (29.2) L, Vdz 119 (41.6) L, and CL 12.2 (3.79) L/h.",Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),[h·ng] / [ml],"27,100",51610,DB08907,Canagliflozin
,27136910,Vdss,"After intravenous administration, the mean (SD) Cmax of unchanged [(14) C]-canagliflozin was 17,605 (6901) ng/mL, AUC∞ 27,100 (10,778) ng.h/mL, Vdss 83.5 (29.2) L, Vdz 119 (41.6) L, and CL 12.2 (3.79) L/h.",Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),l,83.5,51611,DB08907,Canagliflozin
,27136910,Vdz,"After intravenous administration, the mean (SD) Cmax of unchanged [(14) C]-canagliflozin was 17,605 (6901) ng/mL, AUC∞ 27,100 (10,778) ng.h/mL, Vdss 83.5 (29.2) L, Vdz 119 (41.6) L, and CL 12.2 (3.79) L/h.",Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),l,119,51612,DB08907,Canagliflozin
,27136910,CL,"After intravenous administration, the mean (SD) Cmax of unchanged [(14) C]-canagliflozin was 17,605 (6901) ng/mL, AUC∞ 27,100 (10,778) ng.h/mL, Vdss 83.5 (29.2) L, Vdz 119 (41.6) L, and CL 12.2 (3.79) L/h.",Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),[l] / [h],12.2,51613,DB08907,Canagliflozin
,27136910,Cmax,"For total [(14) C] radioactivity, the mean (SD) Cmax was 15,981 (2721) ng-eq/mL, and AUC∞ 53,755 (15,587) ng-eq.h/mL. Renal (34.5% in urine) and biliary (34.1% in feces) excretions were the major elimination pathways for total [(14) C] radioactivity.",Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),[ng-eq] / [ml],"15,981",51614,DB08907,Canagliflozin
,27136910,AUC∞,"For total [(14) C] radioactivity, the mean (SD) Cmax was 15,981 (2721) ng-eq/mL, and AUC∞ 53,755 (15,587) ng-eq.h/mL. Renal (34.5% in urine) and biliary (34.1% in feces) excretions were the major elimination pathways for total [(14) C] radioactivity.",Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),[h·ng-eq] / [ml],"53,755",51615,DB08907,Canagliflozin
,27136910,absolute oral bioavailability,The absolute oral bioavailability of canagliflozin was 65% (90% confidence interval: 55.41; 76.07).,Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27136910/),%,65,51616,DB08907,Canagliflozin
,31588657,time to maximum plasma concentration,"In healthy participants and those with T2DM, rongliflozin was rapidly absorbed, with a time to maximum plasma concentration of 0.63 to 1.75 hours.","Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31588657/),h,0.63 to 1.75,63930,DB08907,Canagliflozin
,25907176,renal glucose threshold,Mean (SE) 24-h mean renal glucose threshold values for b.i.d. and q.d. regimens were 59.2 (1.03) and 60.2 (1.03) mg/dL for the 100 mg daily doses and 51.0 (1.04) and 52.5 (1.04) mg/dL for the 300 mg daily doses.,"Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907176/),[mg] / [dl],59.2,85816,DB08907,Canagliflozin
,25907176,renal glucose threshold,Mean (SE) 24-h mean renal glucose threshold values for b.i.d. and q.d. regimens were 59.2 (1.03) and 60.2 (1.03) mg/dL for the 100 mg daily doses and 51.0 (1.04) and 52.5 (1.04) mg/dL for the 300 mg daily doses.,"Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907176/),[mg] / [dl],60.2,85817,DB08907,Canagliflozin
,25907176,renal glucose threshold,Mean (SE) 24-h mean renal glucose threshold values for b.i.d. and q.d. regimens were 59.2 (1.03) and 60.2 (1.03) mg/dL for the 100 mg daily doses and 51.0 (1.04) and 52.5 (1.04) mg/dL for the 300 mg daily doses.,"Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907176/),[mg] / [dl],51.0,85818,DB08907,Canagliflozin
,25907176,renal glucose threshold,Mean (SE) 24-h mean renal glucose threshold values for b.i.d. and q.d. regimens were 59.2 (1.03) and 60.2 (1.03) mg/dL for the 100 mg daily doses and 51.0 (1.04) and 52.5 (1.04) mg/dL for the 300 mg daily doses.,"Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907176/),[mg] / [dl],52.5,85819,DB08907,Canagliflozin
,25907176,24-h,Mean (SE) values of 24-h urinary glucose excretion for b.i.d. and q.d. regimens were 52.8 (1.94) and 48.6 (1.94) g for the 100 mg daily doses and 58.6 (3.81) and 57.8 (3.81) g for the 300 mg daily doses.,"Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907176/),g,52.8,85820,DB08907,Canagliflozin
,25907176,urinary glucose excretion,Mean (SE) values of 24-h urinary glucose excretion for b.i.d. and q.d. regimens were 52.8 (1.94) and 48.6 (1.94) g for the 100 mg daily doses and 58.6 (3.81) and 57.8 (3.81) g for the 300 mg daily doses.,"Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907176/),g,52.8,85821,DB08907,Canagliflozin
,25907176,urinary glucose excretion,Mean (SE) values of 24-h urinary glucose excretion for b.i.d. and q.d. regimens were 52.8 (1.94) and 48.6 (1.94) g for the 100 mg daily doses and 58.6 (3.81) and 57.8 (3.81) g for the 300 mg daily doses.,"Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907176/),g,48.6,85822,DB08907,Canagliflozin
,25907176,urinary glucose excretion,Mean (SE) values of 24-h urinary glucose excretion for b.i.d. and q.d. regimens were 52.8 (1.94) and 48.6 (1.94) g for the 100 mg daily doses and 58.6 (3.81) and 57.8 (3.81) g for the 300 mg daily doses.,"Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907176/),g,58.6,85823,DB08907,Canagliflozin
,25907176,urinary glucose excretion,Mean (SE) values of 24-h urinary glucose excretion for b.i.d. and q.d. regimens were 52.8 (1.94) and 48.6 (1.94) g for the 100 mg daily doses and 58.6 (3.81) and 57.8 (3.81) g for the 300 mg daily doses.,"Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25907176/),g,57.8,85824,DB08907,Canagliflozin
,32579725,Retardation factor,"Retardation factor values were obtained as 0.22 and 0.52 for the CNZ and the IS, respectively.",Quantitative determination of canagliflozin in human plasma samples using a validated HPTLC method and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32579725/),,0.22,110226,DB08907,Canagliflozin
,32579725,Retardation factor,"Retardation factor values were obtained as 0.22 and 0.52 for the CNZ and the IS, respectively.",Quantitative determination of canagliflozin in human plasma samples using a validated HPTLC method and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32579725/),,0.52,110227,DB08907,Canagliflozin
,32579725,peak plasma concentration,"After oral administration, the peak plasma concentration of CNZ was obtained as 1458.01 ng/ml in 2 h.",Quantitative determination of canagliflozin in human plasma samples using a validated HPTLC method and its application to a pharmacokinetic study in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32579725/),[ng] / [ml],1458.01,110228,DB08907,Canagliflozin
,29271103,UGE,Mean 24-hour UGE increased from 5.3 (10.5) g at baseline to 74.1 (37.4) g with canagliflozin 100 mg and from 0.1 (0.04) g to 68.6 (26.5) g with canagliflozin 300 mg.,Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29271103/),g,5.3,126108,DB08907,Canagliflozin
,29271103,UGE,Mean 24-hour UGE increased from 5.3 (10.5) g at baseline to 74.1 (37.4) g with canagliflozin 100 mg and from 0.1 (0.04) g to 68.6 (26.5) g with canagliflozin 300 mg.,Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29271103/),g,74.1,126109,DB08907,Canagliflozin
,29271103,UGE,Mean 24-hour UGE increased from 5.3 (10.5) g at baseline to 74.1 (37.4) g with canagliflozin 100 mg and from 0.1 (0.04) g to 68.6 (26.5) g with canagliflozin 300 mg.,Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29271103/),g,0.1,126110,DB08907,Canagliflozin
,29271103,UGE,Mean 24-hour UGE increased from 5.3 (10.5) g at baseline to 74.1 (37.4) g with canagliflozin 100 mg and from 0.1 (0.04) g to 68.6 (26.5) g with canagliflozin 300 mg.,Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29271103/),g,68.6,126111,DB08907,Canagliflozin
,26041408,oral bioavailability,Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %.,"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),%,65,135780,DB08907,Canagliflozin
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,10.6,135781,DB08907,Canagliflozin
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,13.1,135782,DB08907,Canagliflozin
,26280756,time to maximum concentration (t max),Plasma canagliflozin maximum concentration and area under the concentration-time curve (AUC) values increased in a dose-dependent manner with the time to maximum concentration (t max) of 1.0 h and elimination half-life (t 1/2) of 10.22-13.26 h on Day 1.,"Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280756/),h,1.0,136945,DB08907,Canagliflozin
,26280756,elimination half-life (t 1/2),Plasma canagliflozin maximum concentration and area under the concentration-time curve (AUC) values increased in a dose-dependent manner with the time to maximum concentration (t max) of 1.0 h and elimination half-life (t 1/2) of 10.22-13.26 h on Day 1.,"Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280756/),h,10.22-13.26,136946,DB08907,Canagliflozin
,25476275,flow rate,"Chromatographic separation of canagliflozin and zafirlukast (IS) was carried out on Acquity BEH C18 column (100×2.1 mm, i.d. 1.7 µm) using acetonitrile-water (80:20, v/v) as mobile phase at a flow rate of 0.3 mL min(-1).",Rapid determination of canagliflozin in rat plasma by UHPLC-MS/MS using negative ionization mode to avoid adduct-ions formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25476275/),[ml] / [min],0.3,137238,DB08907,Canagliflozin
,25476275,m/z,"Multiple reaction monitoring were used for quantitation of precursor to product ion at m/z 443.16 >364.96 for canagliflozin and m/z 574.11>462.07 for IS, respectively.",Rapid determination of canagliflozin in rat plasma by UHPLC-MS/MS using negative ionization mode to avoid adduct-ions formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25476275/),,443.16,137239,DB08907,Canagliflozin
>,25476275,m/z,"Multiple reaction monitoring were used for quantitation of precursor to product ion at m/z 443.16 >364.96 for canagliflozin and m/z 574.11>462.07 for IS, respectively.",Rapid determination of canagliflozin in rat plasma by UHPLC-MS/MS using negative ionization mode to avoid adduct-ions formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25476275/),,364.96,137240,DB08907,Canagliflozin
>,25476275,m/z,"Multiple reaction monitoring were used for quantitation of precursor to product ion at m/z 443.16 >364.96 for canagliflozin and m/z 574.11>462.07 for IS, respectively.",Rapid determination of canagliflozin in rat plasma by UHPLC-MS/MS using negative ionization mode to avoid adduct-ions formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25476275/),,574.11,137241,DB08907,Canagliflozin
>,25476275,m/z,"Multiple reaction monitoring were used for quantitation of precursor to product ion at m/z 443.16 >364.96 for canagliflozin and m/z 574.11>462.07 for IS, respectively.",Rapid determination of canagliflozin in rat plasma by UHPLC-MS/MS using negative ionization mode to avoid adduct-ions formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25476275/),,462.07,137242,DB08907,Canagliflozin
,25476275,maximum plasma concentration,The mean maximum plasma concentration of canagliflozin of 1616.79 ng mL(-1) was achieved in 1.5 h after oral administration of 20 mg kg(-1) in rats.,Rapid determination of canagliflozin in rat plasma by UHPLC-MS/MS using negative ionization mode to avoid adduct-ions formation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25476275/),[ng] / [ml],1616.79,137243,DB08907,Canagliflozin
,32663790,runtime,"Here we report a simple and robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of three SGLT2i (canagliflozin, dapagliflozin and empagliflozin) in human plasma, serum and urine with a runtime of 1 min.","Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32663790/),min,1,140241,DB08907,Canagliflozin
,32663790,flow rate,"Chromatographic separation was accomplished using a Waters ACQUITY UPLC HSS T3 1.8 μm; 2.1 × 50 mm column with a Waters ACQUITY UPLC HSS T3 1.8 μm VanGuard Pre-column; 2.1 × 5 mm, using gradient elution with ammonium acetate 20 mM (pH 5) and acetonitrile as mobile phase at a flow rate of 0.8 ml/min.","Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32663790/),[ml] / [min],0.8,140242,DB08907,Canagliflozin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,27,151996,DB08907,Canagliflozin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,80,151997,DB08907,Canagliflozin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),[μM] / [l],16,151998,DB08907,Canagliflozin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,75,151999,DB08907,Canagliflozin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,19.3,152000,DB08907,Canagliflozin
,27862160,IC50,"In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1).",In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862160/),-1·l·μM,21.5,152001,DB08907,Canagliflozin
,32265061,Tmax,Oral DJT1116PG was rapidly absorbed with a Tmax of 0.75-1.5 h and a t½ of 12-16.2 h.,"A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265061/),h,0.75-1.5,172534,DB08907,Canagliflozin
,32265061,t½,Oral DJT1116PG was rapidly absorbed with a Tmax of 0.75-1.5 h and a t½ of 12-16.2 h.,"A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265061/),h,12-16.2,172535,DB08907,Canagliflozin
,26989857,flow rate,"Following liquid-liquid extraction by tert-butyl methyl ether, chromatographic separation of canagliflozin was performed on a Quicksorb ODS (2.1 mm i.d. × 150 mm, 5 µm size) using acetonitrile-0.1% formic acid (90:10, v/v) as the mobile phase at a flow rate of 0.2 mL/min.","A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26989857/),[ml] / [min],0.2,176746,DB08907,Canagliflozin
,26989857,m/z,Selected ion monitoring transitions of m/z = 462.0 [M + NH4 ](+) → 191.0 for canagliflozin and m/z = 451.2 [M + H](+) → 71.0 for empagliflozin (internal standard) were obtained.,"A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26989857/),,462.0,176747,DB08907,Canagliflozin
,26989857,m/z,Selected ion monitoring transitions of m/z = 462.0 [M + NH4 ](+) → 191.0 for canagliflozin and m/z = 451.2 [M + H](+) → 71.0 for empagliflozin (internal standard) were obtained.,"A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26989857/),,191.0,176748,DB08907,Canagliflozin
,26989857,m/z,Selected ion monitoring transitions of m/z = 462.0 [M + NH4 ](+) → 191.0 for canagliflozin and m/z = 451.2 [M + H](+) → 71.0 for empagliflozin (internal standard) were obtained.,"A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26989857/),M,451.2,176749,DB08907,Canagliflozin
,26989857,m/z,Selected ion monitoring transitions of m/z = 462.0 [M + NH4 ](+) → 191.0 for canagliflozin and m/z = 451.2 [M + H](+) → 71.0 for empagliflozin (internal standard) were obtained.,"A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26989857/),,71.0,176750,DB08907,Canagliflozin
,27604638,inhibition ratios,"In small intestine simulations, the inhibition ratios for SGLT1 were predicted to be 40%-60% after the oral administration of clinical doses (100-300 mg/day).",Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27604638/),%,40,179182,DB08907,Canagliflozin
,27604638,inhibition ratios,"In contrast, inhibition ratios of canagliflozin for renal SGLT2 and SGLT1 were predicted to be approximately 100% and 0.2%-0.4%, respectively.",Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27604638/),%,100,179183,DB08907,Canagliflozin
,27604638,inhibition ratios,"In contrast, inhibition ratios of canagliflozin for renal SGLT2 and SGLT1 were predicted to be approximately 100% and 0.2%-0.4%, respectively.",Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27604638/),%,0.2,179184,DB08907,Canagliflozin
,27604638,inhibition ratios,"In contrast, inhibition ratios of canagliflozin for renal SGLT2 and SGLT1 were predicted to be approximately 100% and 0.2%-0.4%, respectively.",Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27604638/),%,0.4,179185,DB08907,Canagliflozin
,31177048,flow rate,"Prior Chromatographic separation on an Agilent Eclipse Plus C18 (4.6 × 100 mm, 3.5 μm) using gradient mobile phase system consisting of ammonium formate pH 4.5 and acetonitrile at a flow rate of 0.5 mL min-1, within a run time of 14 min, the antidiabetic drugs were extracted from rat plasma using acetonitrile-induced protein precipitation technique.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),[ml] / [min],0.5,194137,DB08907,Canagliflozin
,31177048,run time,"Prior Chromatographic separation on an Agilent Eclipse Plus C18 (4.6 × 100 mm, 3.5 μm) using gradient mobile phase system consisting of ammonium formate pH 4.5 and acetonitrile at a flow rate of 0.5 mL min-1, within a run time of 14 min, the antidiabetic drugs were extracted from rat plasma using acetonitrile-induced protein precipitation technique.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),min,14,194138,DB08907,Canagliflozin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,130.1,194139,DB08907,Canagliflozin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,71,194140,DB08907,Canagliflozin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,357.2,194141,DB08907,Canagliflozin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,134.2,194142,DB08907,Canagliflozin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,462.16,194143,DB08907,Canagliflozin
,31177048,m/z,"Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130.1 → 71.0 & 60 for MET, 357.2 → 134.2 for PGT, and 462.16 → 191.1 for CAN.",Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31177048/),,191.1,194144,DB08907,Canagliflozin
,22226086,elimination half-life,"Canagliflozin pharmacokinetics were dose-dependent, and the elimination half-life ranged from 12 to 15 h.",Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22226086/),h,12 to 15,204020,DB08907,Canagliflozin
,32126254,CL,"Human predicted CL, Vss and F were 1.04 L/h, 77.5 L and 0.80.","Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32126254/),[l] / [h],1.04,213385,DB08907,Canagliflozin
,32126254,Vss,"Human predicted CL, Vss and F were 1.04 L/h, 77.5 L and 0.80.","Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32126254/),l,77.5,213386,DB08907,Canagliflozin
,32126254,F,"Human predicted CL, Vss and F were 1.04 L/h, 77.5 L and 0.80.","Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32126254/),,0.80,213387,DB08907,Canagliflozin
,26687552,Cmax,"After the administration of single doses of 200 and 300 mg, the mean (SD) Cmax values were 1792 (430) ng/mL and 2789 (941) ng/mL, respectively; AUC0-∞, values were 18,706 (3818) ng·h/mL and 28,207 (5901) ng·h/mL, respectively.","Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687552/),[ng] / [ml],1792,217057,DB08907,Canagliflozin
,26687552,Cmax,"After the administration of single doses of 200 and 300 mg, the mean (SD) Cmax values were 1792 (430) ng/mL and 2789 (941) ng/mL, respectively; AUC0-∞, values were 18,706 (3818) ng·h/mL and 28,207 (5901) ng·h/mL, respectively.","Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687552/),[ng] / [ml],2789,217058,DB08907,Canagliflozin
,26687552,AUC0-∞,"After the administration of single doses of 200 and 300 mg, the mean (SD) Cmax values were 1792 (430) ng/mL and 2789 (941) ng/mL, respectively; AUC0-∞, values were 18,706 (3818) ng·h/mL and 28,207 (5901) ng·h/mL, respectively.","Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687552/),[h·ng] / [ml],"18,706",217059,DB08907,Canagliflozin
,26687552,AUC0-∞,"After the administration of single doses of 200 and 300 mg, the mean (SD) Cmax values were 1792 (430) ng/mL and 2789 (941) ng/mL, respectively; AUC0-∞, values were 18,706 (3818) ng·h/mL and 28,207 (5901) ng·h/mL, respectively.","Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687552/),[h·ng] / [ml],"28,207",217060,DB08907,Canagliflozin
,26687552,Tmax,"The Tmax and t½ of canagliflozin were independent of dose (Tmax, 1.5 hours at both doses; t½, 13.0 and 12.6 hours with 200 and 300 mg).","Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687552/),h,1.5,217061,DB08907,Canagliflozin
,26687552,t½,"The Tmax and t½ of canagliflozin were independent of dose (Tmax, 1.5 hours at both doses; t½, 13.0 and 12.6 hours with 200 and 300 mg).","Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687552/),h,13.0,217062,DB08907,Canagliflozin
,26687552,t½,"The Tmax and t½ of canagliflozin were independent of dose (Tmax, 1.5 hours at both doses; t½, 13.0 and 12.6 hours with 200 and 300 mg).","Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687552/),h,12.6,217063,DB08907,Canagliflozin
,26687552,renal threshold for glucose (RTG),"Over the first 4 hours, mean (SD) renal threshold for glucose (RTG) values were 60.8 (8.90) and 61.2 (7.04) mg/dL with the 200- and 300-mg doses, respectively.","Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687552/),[mg] / [dl],60.8,217064,DB08907,Canagliflozin
,26687552,renal threshold for glucose (RTG),"Over the first 4 hours, mean (SD) renal threshold for glucose (RTG) values were 60.8 (8.90) and 61.2 (7.04) mg/dL with the 200- and 300-mg doses, respectively.","Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26687552/),[mg] / [dl],61.2,217065,DB08907,Canagliflozin
,30295193,bioavailability enhancement,"Enhanced in vitro dissolution rate of optimized solid SMEDDS manifested in bioavailability enhancement of 167.54% and 188.98%, as compared to pure drug and marketed product.",Role of Porous Carriers in the Biopharmaceutical Performance of Solid SMEDDS of Canagliflozin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30295193/),%,167.54,226367,DB08907,Canagliflozin
,30295193,bioavailability enhancement,"Enhanced in vitro dissolution rate of optimized solid SMEDDS manifested in bioavailability enhancement of 167.54% and 188.98%, as compared to pure drug and marketed product.",Role of Porous Carriers in the Biopharmaceutical Performance of Solid SMEDDS of Canagliflozin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30295193/),%,188.98,226368,DB08907,Canagliflozin
,26048186,AUC0-∞,"Mean AUC and Cmax of canagliflozin increased in a dose-dependent manner after single-dose administration (AUC0-∞, 10,521 ng · h/mL for 100 mg, 33,583 ng · h/mL for 300 mg; Cmax, 1178 ng/mL for 100 mg, 4113 ng/mL for 300 mg).","Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26048186/),[h·ng] / [ml],"10,521",228534,DB08907,Canagliflozin
,26048186,AUC0-∞,"Mean AUC and Cmax of canagliflozin increased in a dose-dependent manner after single-dose administration (AUC0-∞, 10,521 ng · h/mL for 100 mg, 33,583 ng · h/mL for 300 mg; Cmax, 1178 ng/mL for 100 mg, 4113 ng/mL for 300 mg).","Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26048186/),[h·ng] / [ml],"33,583",228535,DB08907,Canagliflozin
,26048186,Cmax,"Mean AUC and Cmax of canagliflozin increased in a dose-dependent manner after single-dose administration (AUC0-∞, 10,521 ng · h/mL for 100 mg, 33,583 ng · h/mL for 300 mg; Cmax, 1178 ng/mL for 100 mg, 4113 ng/mL for 300 mg).","Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26048186/),[ng] / [ml],1178,228536,DB08907,Canagliflozin
,26048186,Cmax,"Mean AUC and Cmax of canagliflozin increased in a dose-dependent manner after single-dose administration (AUC0-∞, 10,521 ng · h/mL for 100 mg, 33,583 ng · h/mL for 300 mg; Cmax, 1178 ng/mL for 100 mg, 4113 ng/mL for 300 mg).","Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26048186/),[ng] / [ml],4113,228537,DB08907,Canagliflozin
,26048186,t½,"The mean apparent t½ and the median Tmax of canagliflozin were independent of dose (t½, 16.0 hours for 100 mg, 16.2 hours for 300 mg; Tmax, ~1 hour).","Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26048186/),h,16.0,228538,DB08907,Canagliflozin
,26048186,t½,"The mean apparent t½ and the median Tmax of canagliflozin were independent of dose (t½, 16.0 hours for 100 mg, 16.2 hours for 300 mg; Tmax, ~1 hour).","Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26048186/),h,16.2,228539,DB08907,Canagliflozin
,26048186,Tmax,"The mean apparent t½ and the median Tmax of canagliflozin were independent of dose (t½, 16.0 hours for 100 mg, 16.2 hours for 300 mg; Tmax, ~1 hour).","Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26048186/),h,1,228540,DB08907,Canagliflozin
,26048186,urinary glucose excretion,"Canagliflozin decreased the 24-hour mean renal threshold for glucose, calculated by using measured creatinine clearance to estimate the glomerular filtration rate (67.9 and 60.7 mg/dL for canagliflozin 100 and 300 mg, respectively) and 24-hour increased urinary glucose excretion (33.8 and 42.9 g for canagliflozin 100 and 300 mg, respectively) in a dose-dependent manner; the 24-hour plasma glucose profile remained largely unchanged.","Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26048186/),g,33.8,228541,DB08907,Canagliflozin
,26048186,urinary glucose excretion,"Canagliflozin decreased the 24-hour mean renal threshold for glucose, calculated by using measured creatinine clearance to estimate the glomerular filtration rate (67.9 and 60.7 mg/dL for canagliflozin 100 and 300 mg, respectively) and 24-hour increased urinary glucose excretion (33.8 and 42.9 g for canagliflozin 100 and 300 mg, respectively) in a dose-dependent manner; the 24-hour plasma glucose profile remained largely unchanged.","Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26048186/),g,42.9,228542,DB08907,Canagliflozin
,25424014,AUC0.5 - 4h,"Mean AUC0.5 - 4h increased post-meal, on combination therapy, from 9.6 to 12.5 pmol·h/l (active GLP-1) and from 21.5 to 32.3 pmol·h/l (total GLP-1).",Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25424014/),[h·pM] / [l],9.6 to 12.5,236155,DB08907,Canagliflozin
,25424014,AUC0.5 - 4h,"Mean AUC0.5 - 4h increased post-meal, on combination therapy, from 9.6 to 12.5 pmol·h/l (active GLP-1) and from 21.5 to 32.3 pmol·h/l (total GLP-1).",Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25424014/),[h·pM] / [l],21.5 to 32.3,236156,DB08907,Canagliflozin
,29783787,flow rate,"Following liquid⁻liquid extraction by tert-butyl methyl ether, chromatographic separation of canagliflozin and its metabolites were performed on a Waters XBridge BEH C18 column (100 × 2.1 mm, 2.5 μm) using 0.1% acetonitrile⁻formic acid (75:15, v/v) as the mobile phase at a flow rate of 0.7 mL/min.",Plasma Pharmacokinetic Determination of Canagliflozin and Its Metabolites in a Type 2 Diabetic Rat Model by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29783787/),[ml] / [min],0.7,242232,DB08907,Canagliflozin
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,260.2,258990,DB08907,Canagliflozin
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,183.0,258991,DB08907,Canagliflozin
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,390.2,258992,DB08907,Canagliflozin
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,268.2,258993,DB08907,Canagliflozin
higher,31384829,recoveries,All obtained recoveries were higher than 90.0% while the accuracy was in the range of 88.14-113.05% and the relative standard deviation was below 10.0% for all investigated drugs by the proposed method.,Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),%,90.0,258994,DB08907,Canagliflozin
,23412078,UGE0-6h,"Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC0-2h] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE0-6h, 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed RaO.","Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23412078/),g,18.2,269383,DB08907,Canagliflozin
,23412078,total AUC Ra,"Over 2 to 6 h, canagliflozin increased RaO such that total AUC RaO over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003).","Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23412078/),[mg] / [kg],960,269384,DB08907,Canagliflozin
,23412078,total AUC Ra,"Over 2 to 6 h, canagliflozin increased RaO such that total AUC RaO over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003).","Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23412078/),[mg] / [kg],"1,018",269385,DB08907,Canagliflozin
